Pediatric Pituitary Tumor Survivors Face a Fragile Hand-Off to Adult Care
Pediatric patients with pituitary tumors often enter adulthood carrying more than a diagnosis. They leave behind a care structure built for childhood and step into a system that may not be ready to absorb the long-term consequences of surgery, radiation, hormone deficiency, visual injury, metabolic change, or neurocognitive burden.
The transition is happening at the exact moment when life is becoming more complicated. Puberty is ending, peak bone mass is still being established, and young people are learning how to live independently, manage insurance, navigate college or work, and make decisions about alcohol, drugs, fertility, and self-care.
Kevin C. J. Yuen, MD, FRCP, FEAA, used his ENDO 2026 Meet-the-Professor session to frame that handoff as a clinical problem that can be mitigated if clinicians recognize the risk early enough. His message was direct: the gap is real, the consequences are durable, and the solution begins long before the pediatric visit ends.
Why This Transition Becomes So Unforgiving
Pediatric pituitary tumors are not simply smaller versions of adult disease. In children, these tumors are often larger, more aggressive, and more likely to intersect with growth, sexual maturation, fertility, bone quality, cardiovascular health, and metabolism. Some also occur in the setting of genetic syndromes, which adds another layer of complexity to surveillance and treatment planning.
Therapeutic options are narrower in children, and medical therapy may work less reliably than it does in adults. When surgery or radiation leaves permanent endocrine deficits, lifelong management is rarely straightforward. Replacement regimens may need to be adjusted repeatedly over time, and the burden is amplified when other sequelae are present, including visual impairment, psychiatric disorders, and neurocognitive dysfunction.
The clinical stakes are practical. If a patient never becomes established with an adult endocrinologist, years can pass before problems resurface, often after growth has ended and the original pediatric team has already moved on. By then, the presentation may no longer be about tumor survivorship alone; it may involve obesity, bone fragility, loss of muscle mass, infertility, or cardiometabolic disease.
Existing Transition Frameworks Offer Structure, Not Magic
Yuen pointed to established transition models as proof that this problem can be organized rather than improvised. The six core elements of health care transition — transition policy, transition tracking and monitoring, readiness assessment, transition planning, transfer of care, and transfer completion — give clinicians a framework for preventing patients from slipping through the cracks.
The UK’s Ready Steady Go program adds another layer of structure. It begins early, around age 11, and moves patients through a staged process designed to build self-management skills and ensure a deliberate transfer into adult services. The sequence is simple in concept and demanding in execution: Ready, Steady, Go, then Hello.
A pediatric endocrine transition plan works best when it is treated as a process rather than a single referral. That means identifying the adult clinician before the transfer becomes urgent, preparing the family for the handoff, and making sure the patient understands what lifelong endocrine surveillance may involve.
The U.S. Setting Complicates the Ideal Path
The American system does not easily accommodate a single transition template. Fragmented payers, distance between institutions, and uneven access to subspecialists can all alter what happens in real life. Some children’s hospitals are far from adult endocrinology clinics, and some communities simply do not have a dedicated neuroendocrinologist.
Insurance coverage can also push treatment away from the best-evidenced option and toward what is accessible. In that setting, clinicians may have to choose the best available alternative rather than the optimal one they would have preferred. The result is a series of compromises that are familiar in medicine but especially consequential for a population with rare, chronic disease.
Rare disease amplifies every break in continuity. A young person with a pituitary tumor survivor history is not just moving between clinics; they are moving between entire models of care.
Growth Hormone Testing, Bone Health, and the Risk of Delay
Even basic questions can become surprisingly unsettled during transfer. Yuen described uncertainty about who should order growth hormone testing at the point of transition — the pediatric endocrinologist or the adult specialist receiving the patient. The issue is not bureaucratic. It determines whether a patient receives timely reassessment or remains off therapy for years.
The transition period is especially important for patients who received growth hormone in childhood. Treatment may not end when final height is reached, because biochemical testing can show persistent deficiency that affects body composition, bone, heart, muscle, and quality of life. A European audit found that about 70% of patients experienced a growth hormone treatment interruption lasting more than two years during this period.
A two-year gap is not a clerical error. It is enough time for endocrine deficits to shape adult physiology in ways that become harder to reverse. For patients who were treated as children for growth, the adult priorities often shift toward bone integrity, strength, cardiometabolic health, and functional status.
Early Counseling Changes the Odds
The best moment to start transition planning is not when the patient ages out of pediatric care. It is earlier, while the family is still engaged and the patient is still learning the language of chronic disease.
Yuen emphasized early discussion, patient empowerment, and long-term surveillance with a multidisciplinary team. Those principles are especially important for patients with craniopharyngiomas and hypothalamic obesity, where weight gain may accelerate early and then persist into adulthood if not addressed promptly. Once that trajectory is established, it does not simply disappear with time.
Patient education also has a behavioral dimension. Young adults need to understand that endocrine care may be lifelong, that medications may need repeated adjustment, and that fertility, bone health, mental health, and metabolic risk belong in the same conversation. The more that responsibility is shared early, the less likely the patient is to disappear into the gap between pediatric and adult systems.
Empowerment Is Part of the Treatment Plan
The joint ESPE and ESE guidance published in the European Journal of Endocrinology reinforces a principle clinicians often state but do not always operationalize: transition is not just transfer. It is preparation.
Preparation means helping the patient take ownership of the disease while preserving a strong relationship with the care team. It also means accepting that endocrine transition is multidisciplinary by necessity. Fertility counseling, bone assessment, psychological support, and metabolic follow-up all belong in the same pathway when pituitary disease has altered development over years.
One sentence captures the practical approach. Start early.
Another captures the consequence of delay. Lost follow-up can become lost years.
Yuen’s closing message was not that every institution should copy the same model. It was that every institution should identify its own vulnerabilities, define responsibilities clearly, and build a transition plan before the patient has already disappeared from pediatric care. The unanswered question is not whether the gap exists; it is how many health systems will close it before more young adults reach the emergency room, the obesity clinic, or the infertility workup with a history that should have been followed all along.